Drug Information

Drug General Information
Drug ID
D03UZC
Former ID
DIB001560
Drug Name
DS-1150b
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 1 [524558]
Company
Daiichi sankyo
Target and Pathway
Target(s) Solute carrier family 2, facilitated glucose transporter, member 4 Target Info Modulator [551213]
KEGG Pathway FoxO signaling pathway
AMPK signaling pathway
Insulin signaling pathway
Adipocytokine signaling pathway
Type II diabetes mellitus
Pathway Interaction Database Arf6 trafficking events
Insulin-mediated glucose transport
Class I PI3K signaling events mediated by Akt
PathWhiz Pathway Glucose-Alanine Cycle
Insulin Signalling
Reactome Translocation of GLUT4 to the plasma membrane
Transcriptional regulation of white adipocyte differentiation
Facilitative Na+-independent glucose transporters
Glucose transport
WikiPathways Glycolysis and Gluconeogenesis
Insulin Signaling
NRF2 pathway
Vitamin D Receptor Pathway
Translocation of GLUT4 to the Plasma Membrane
Transcriptional Regulation of White Adipocyte Differentiation
Adipogenesis
Cori Cycle
Hexose transport
Type II diabetes mellitus
AMPK Signaling
References
Ref 524558ClinicalTrials.gov (NCT02004678) Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus. U.S. National Institutesof Health.
Ref 551213Sanford-Burnham goes fourth. SciBX 7(22); doi:10.1038/scibx.2014.633. June 5 2014

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.